BIO 2019 Maryland Pavilion
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
Published on :Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, [….]
BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time
Published on :BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time March 12, 2019 In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological [….]
Viela Bio’s Spinout Story Reveals A Roadmap for Growth Ahead
Published on :Viela Bio’s Spinout Story Reveals A Roadmap for Growth Ahead November 6, 2018 In order: Elizabeth Parsons (Member, Mintz Levin), Aaron Ren (Head of BD and Operations, Viela Bio), Christian [….]